Lei An

Prof. Dr. Lei An

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
XZXiaodan Zheng
Xiaodan Zheng
YGYuqi Guo
Yuqi Guo
LWLei Wang
Lei Wang
HZHonghai Zhang
Honghai Zhang
SWShaobo Wang
Shaobo Wang
CYChengfang Yao
Chengfang Yao

5 November 2022 in Translational Research
Verified
Journal Article
Open access
LALei An
Lei An
YWYueqiang Wang
Yueqiang Wang
GWGuangyao Wu
Guangyao Wu
ZWZhenxing Wang
Zhenxing Wang
ZSZeyuan Shi
Zeyuan Shi
HXHongen Xu
Hongen Xu
Tyrosine kinase inhibitor (TKI) is a standard treatment for patients with NSCLC harboring constitutively active epidermal growth factor receptor (EGFR) mutations. However, most rare EGFR mutations lack treatment regimens except for the well-studied ones. We constructed two EGFR variant libraries containing substitutions, deletions, or insertions using the saturation mutagenesis method. All the variants were located in the EGFR mutation hotspot (exons 18-21). The sensitivity of these variants to afatinib, erlotinib, gefitinib, icotinib, and osimertinib was systematically studied by determining their enrichment in massively parallel cytotoxicity assays using an endogenous EGFR-depleted cell line. A total of 3914 and 70,475 variants were detected in the constructed EGFR Substitution-Deletion (Sub-Del) and exon 20 Insertion (Ins) libraries. Of the 3914 Sub-Del variants, 221 proliferated fast in the control assay and were sensitive to EGFR-TKIs. For the 70,475 Ins variants, insertions at amino acid positions 770-774 were highly enriched in all 5 TKI cytotoxicity assays. Moreover, the top 5% of the enriched insertion variants included a glycine or serine insertion at high frequency. We present a comprehensive reference for the sensitivity of EGFR variants to five commonly used TKIs. The approach used here should be applicable to other genes and targeted drugs.

27 March 2023 in Biology
Verified
Journal Article
Open access
PDF file
LMLu Mao
Lu Mao
YWYueqiang Wang
Yueqiang Wang
LALei An
Lei An
BZBeiping Zeng
Beiping Zeng
YWYanyan Wang
Yanyan Wang
HXHongen Xu
Hongen Xu
The GJB2 gene is the most common gene responsible for hearing loss (HL) worldwide, and missense variants are the most abundant type. GJB2 pathogenic missense variants cause nonsyndromic HL (autosomal recessive and dominant) and syndromic HL combined with skin diseases. However, the mechanism by which these different missense variants cause the different phenotypes is unknown. Over 2/3 of the GJB2 missense variants have yet to be functionally studied and are currently classified as variants of uncertain significance (VUS). Based on these functionally determined missense variants, we reviewed the clinical phenotypes and investigated the molecular mechanisms that affected hemichannel and gap junction functions, including connexin biosynthesis, trafficking, oligomerization into connexons, permeability, and interactions between other coexpressed connexins. We predict that all possible GJB2 missense variants will be described in the future by deep mutational scanning technology and optimizing computational models. Therefore, the mechanisms by which different missense variants cause different phenotypes will be fully elucidated.

12 October 2023 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
ZWZhenxing Wang
Zhenxing Wang
LLLanxin Li
Lanxin Li
CCChunhong Chu
Chunhong Chu
XWXiangkai Wei
Xiangkai Wei
QLQian Liu
Qian Liu
XLXiao dong Li
Xiao dong Li
Bladder cancer is one of the most common urological malignancies worldwide. The molecular mechanism underlying its development is complex, but its carcinogenesis has been proposed to occur with cell proliferation and resistance to apoptosis, driven by the signaling activity of abundant EGFR and receptor tyrosine‑protein kinase erbB‑2. In the present study, T24 bladder cancer cell lines with EGFR‑overexpression were constructed, before the multi‑target inhibitor CUDC‑101 was used to investigate its potential as a targeted therapeutic agent for bladder cancer using chemosensitivity methods. The results showed that CUDC‑101 induced cytotoxic effects, inhibited growth vitality and proliferation in a dose‑dependent manner. CUDC‑101 also altered the skeletal morphology and microfilament structure, while blocking cell cycle progression and causing apoptosis. These results supported the proposed cytotoxic effects of CUDC‑101, in addition to its inhibitory effects on cell division and proliferation in EGFR‑overexpressing bladder cancer cells. Therefore CUDC‑101 may to be a potential therapeutic option for the treatment of bladder cancer.

20 January 2023 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
YWYing Wang
Ying Wang
QLQian Liu
Qian Liu
CCChunhong Chu
Chunhong Chu
LLLanxin Li
Lanxin Li
ZWZhenxing Wang
Zhenxing Wang
JMjiguang ma
jiguang ma

6 June 2022 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
CLChang Liu
Chang Liu
ZWZhenxing Wang
Zhenxing Wang
QLQian Liu
Qian Liu
GWGuangyao Wu
Guangyao Wu
CCChunhong Chu
Chunhong Chu
SDShao-Feng Duan
Shao-Feng Duan